



Final Appraisal Recommendation

Advice No: 2812 – September 2012

Trastuzumab (Herceptin[®]▼) 150 mg powder for concentrate for solution for infusion

Limited submission by Roche Products Ltd

Recommendation of AWMSG

Trastuzumab (Herceptin[®]▼) 150 mg powder for concentrate for solution for infusion is recommended as an option for use within NHS Wales for the treatment of HER2 positive early breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.

Additional note:

- AWMSG are of the opinion that trastuzumab (Herceptin[®]▼) is appropriate for specialist only prescribing within NHS Wales for the indication under consideration.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Roche Products Ltd
Date of first issue	September 2012
Last reviewed	August 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2812:
Trastuzumab (Herceptin[®]▼) 150 mg powder for concentrate for solution for infusion. September 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.